- Home
- CDLX vs MREO Comparison
CDLX vs MREO Comparison
Compare CDLX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDLX | MREO |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.3M | 52.5M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CDLX | MREO |
|---|---|---|
| Price | $0.88 | $0.33 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $2.25 | $1.50 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.13 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $233,273,000.00 | $500,000.00 |
| Revenue This Year | N/A | $6,000.20 |
| Revenue Next Year | $8.82 | $34.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.67 | $0.20 |
| 52 Week High | $3.28 | $2.94 |
Technical Indicators
Market Signals| Indicator | CDLX | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 41.57 |
| Support Level | $0.88 | $0.32 |
| Resistance Level | $1.11 | $0.42 |
| Average True Range (ATR) | 0.13 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 4.11 | 42.31 |
Price Performance
Historical ComparisonAbout CDLX Cardlytics Inc.
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).